Date: 2025-07-17
Humana is one of the largest U.S. health insurers, focusing on Medicare Advantage and diversified health service offerings. It earns through monthly premiums, provider reimbursements (HMOs/PPOs), and care-delivery services.
Is the business model simple and sustainable?
Yes. It’s subscription-based healthcare delivery. Premiums and government funding form stable revenue sources, with predictable risk pools and actuarial control.
Does Humana have a durable competitive advantage?
Narrow moat: scale in Medicare Advantage, a growing insured population, integrated care capabilities.
Competitors & positioning:
Main peers are UnitedHealth (UNH), Cigna, Centene. Humana excels in senior care and vertically integrated care delivery, though it remains smaller than UNH.
Is management aligned with shareholders?
Yes. Return on equity ≈ 9.6% and ROIC 5‑year avg ≈ 10.3% reflect prudent investment. Share count is down ~6.7% over 5 years; dividends and buybacks support capital returns.
Is the stock undervalued relative to intrinsic value?
Slightly overvalued. Intrinsic value ~$214 vs. current ~$237 — little margin of safety.
Does the company use capital efficiently?
Yes. The 5-year ROIC of 10.3% exceeds healthcare sector norms and reflects disciplined capital investment.
Does it generate strong FCF?
Yes. FCF (TTM) = $2.38 B; 5‑year avg = $2.87 B. Cash flow comfortably covers dividends and debt obligations.
Is the balance sheet strong?
Moderate. Debt/Equity = 0.75; LTL/5‑yr FCF = 4.6× (under 5× threshold). No dangerous debt levels.
How consistent is earnings and revenue growth?
Revenue 5‑year CAGR ~12%, 10‑year ~9%. Net income declined, however, recent favorable margins and increasing Medicare enrollment support improvement.
Margin of safety?
Minimal. Market price exceeds intrinsic value — no buffer for pricing downside.
Biggest risks:
Reimbursement policy changes, regulatory scrutiny, inflation, high debt, and competition from larger insurers.
Shareholder dilution?
No major dilution. Acquisitions financed through debt/cash, no disruptive equity issuance.
Cyclicality & recession risk:
Stable. Healthcare demand is recession-resistant, especially for Medicare.
5–10 Year Outlook:
Continued enrollment growth, margin expansion through value-based care, moderate M&A, and more member-integrated services.
Would I buy if market closed 5 years?
No, not at today’s price. Downside from my target likely limits total return below 9%.
Reinvestments and shareholder returns:
Balanced: investing in care delivery integration, returning cash via dividends (1.6% yield) and buybacks.
Market mispricing?
Market may be putting a premium for healthcare stability and reimbursement tailwinds, pushing valuations above fair value.
Key assumptions and falsification:
Assumes continued 10% short-term FCF growth, 3% long-term growth, 9% discount rate. Wrong if healthcare policy tightens, competition erodes margins, or profitability slows.
Portfolio fit:
Good for defensive income and sector diversification, but overvalued for a 9% required return strategy.
Intrinsic Value Calculation for Humana (HUM)
Assumptions:
- Free Cash Flow (TTM): $2.38 B
- Growth (Years 1–5): 10% annually (reflecting ~12% 5‑year revenue CAGR)
- Terminal Growth Rate: 3%
- Discount Rate: 9% (your required return)
- Net Debt: EV – Market Cap = $55.88B – $27.01B ≈ $28.9 B
- Shares Outstanding: ~114 M (est. from market cap / share price of $237)
Cash Flow Projections:
- Yr 1: $2.62 B
- Yr 2: $2.88 B
- Yr 3: $3.16 B
- Yr 4: $3.48 B
- Yr 5: $3.83 B
Terminal Value ≈ $66.2 B
PV of FCF (Y1–5) ≈ $11.3 B
PV of Terminal ≈ $42.0 B
→ Enterprise Value: $53.3 B
→ Equity Value: $24.4 B
→ Intrinsic Value / Share: $24.4 B ÷ 114 M ≈ $214
Current share price (~$237) implies Humana is slightly overvalued relative to a 9% return target.
Final Recommendation
- Intrinsic Value: ~$214
- Current Price: ~$237
- Upside/Downside: ~–10%
- Return Expectation at Current Price: Below 9%
- Recommendation: HOLD if already owned; AVOID new purchases until price drops to $180–200 (~15–20% discount for margin of safety).
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a financial advisor before making investment decisions.
